Purification of a cystic fibrosis plasmid vector for gene therapy using hydrophobic interaction chromatography

The success and validity of gene therapy and DNA vaccination in in vivo experiments and human clinical trials depend on the ability to produce large amounts of plasmid DNA according to defined specifications. A new method is described for the purification of a cystic fibrosis plasmid vector (pCF1‐CFTR) of clinical grade, which includes an ammonium sulfate precipitation followed by hydrophobic interaction chromatography (HIC) using a Sepharose gel derivatized with 1,4‐butanediol‐diglycidylether. The use of HIC took advantage of the more hydrophobic character of single‐stranded nucleic acid impurities as compared with double‐stranded plasmid DNA. RNA, denatured genomic and plasmid DNAs, with large stretches of single strands, and lipopolysaccharides (LPS) that are more hydrophobic than supercoiled plasmid, were retained and separated from nonbinding plasmid DNA in a 14‐cm HIC column. Anion‐exchange HPLC analysis proved that >70% of the loaded plasmid was recovered after HIC. RNA and denatured plasmid in the final plasmid preparation were undetectable by agarose electrophoresis. Other impurities, such as host genomic DNA and LPS, were reduced to residual values with the HIC column (<6 ng/μg pDNA and 0.048 EU/μg pDNA, respectively). The total reduction in LPS load in the combined ammonium acetate precipitation and HIC was 400,000‐fold. Host proteins were not detected in the final preparation by bicinchoninic acid (BCA) assay and sodium dodecylsulfate‐polyacrylamide gel electrophoresis (SDS‐PAGE) with silver staining. Plasmid identity was confirmed by restriction analysis and biological activity by transformation experiments. The process presented constitutes an advance over existing methodologies, is scaleable, and meets quality standards because it does not require the use of additives that usually pose a challenge to validation and raise regulatory concerns. © 2000 John Wiley & Sons, Inc. Biotechnol Bioeng 68: 576–583, 2000.

[1]  H. Birnboim,et al.  A rapid alkaline extraction procedure for screening recombinant plasmid DNA. , 1979, Nucleic acids research.

[2]  J. Porath,et al.  Preparation of adsorbents for biospecific affinity chromatography. Attachment of group-containing ligands to insoluble polymers by means of bifuctional oxiranes. , 1974, Journal of chromatography.

[3]  J. Queiroz,et al.  Hydrophobic interaction chromatography of Chromobacterium viscosum lipase , 1995 .

[4]  C. Cooney,et al.  Preparative purification of supercoiled plasmid DNA using anion-exchange chromatography. , 1998, Journal of chromatography. A.

[5]  I. Wicks,et al.  Bacterial lipopolysaccharide copurifies with plasmid DNA: implications for animal models and human gene therapy. , 1995, Human gene therapy.

[6]  C L Cooney,et al.  Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecks. , 1999, Trends in biotechnology.

[7]  C L Cooney,et al.  Purification of plasmids by triplex affinity interaction. , 1998, Nucleic acids research.

[8]  M. M. Diogo,et al.  Separation and analysis of plasmid denatured forms using hydrophobic interaction chromatography. , 1999, Analytical biochemistry.

[9]  M. Marquet,et al.  Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. , 1995, Human gene therapy.

[10]  R. Scheule,et al.  Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. , 1996, Human gene therapy.

[11]  R. Hancock,et al.  Chapter 12 Molecular organization and structural role of outer membrane macromolecules , 1994 .

[12]  F. Ledley Nonviral gene therapy: the promise of genes as pharmaceutical products. , 1995, Human gene therapy.

[13]  J. Cabral,et al.  Development of Process Flow Sheets for the Purification of Supercoiled Plasmids for Gene Therapy Applications , 1999 .